Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19

• DOI: 10.1016/j.isci.2022.103971
• Publication Date: 2022-02-23T00:03:20Z
• Authors: Jun Wang; Prasanti Kotagiri; Paul A. Lyons; Rafia S. Al-Lamki; Federica Mescia; Laura Bergamaschi; Lorinda Turner; Michael D. Morgan; Fernando J. Caler...; Karsten Bach; Nicole Mende; Nicola K. Wilson; Emily R. Watts; Patrick H. Maxwell; Patrick F. Chinnery; Nathalie Kingston; Sofia Papadia; Kathleen E. Stirrups; Neil Walker; Ravindra K. Gupta; David K. Menon; Kieren Allinson; Sarah J. Aitken; Mark Toshner; Michael P. Weekes; James A. Nathan; Sarah R. Walmsley; Willem H. Ouwehand; Mary Kasanicki; Berthold Göttgens; John C. Marioni; Kenneth G.C. Smith; Jordan S. Pober; John R. Bradley
• Keywords: 2019-20 coronavirus outbreak

Clotting Factor V (FV) is primarily synthesized in the liver and when cleaved by thrombin forms pro-coagulant Va (FVa). Using whole blood RNAseq scRNAseq of peripheral mononuclear cells, we find that FV mRNA expressed leukocytes, identify neutrophils, monocytes, T regulatory cells as sources increased hospitalized patients with COVID-19. Proteomic analysis confirms circulating neutrophils severe COVID-19, immunofluorescence microscopy identifies lung-infiltrating leukocytes COVID-19 lung disease. Increased leukocyte expression disease correlates T-cell lymphopenia. Both plasma-derived a cleavage resistant recombinant FV, but not FVa, suppress proliferation